A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

Tirzepatide 30mg
Dual GLP-1 / GIP Incretin Agonist — 30mg Presentation

Compound Specifications
Tirzepatide 30mg
Dual GLP-1 / GIP Incretin Agonist — 30mg Presentation
Tirzepatide 30mg is a higher-strength dual GIP and GLP-1 receptor co-agonist in a 3mL vial, evaluated in clinical programs for advanced metabolic weight management under physician supervision.
Engages both GIP and GLP-1 incretin receptors to enhance beta-cell responsiveness, support adipose lipid metabolism, and reduce appetite signaling.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Administered once weekly subcutaneously, titrated under physician direction to the 30mg presentation.
Frequently Asked Clinical Questions
How is the 30mg presentation used?
The 30mg presentation supports continued metabolic management after physician-guided titration; dosing is individualized by a licensed provider.